Canaccord analyst John Newman was out pounding the table on shares of Synergy Pharmaceuticals Inc (NASDAQ:SGYP), reiterating a buy rating and price target of $13, …
As both earnings and election season are coming to a close, analysts are chiming in with varied expectations for three biotech players: Valeant …
Synergy Pharmaceuticals Inc (NASDAQ:SGYP) announced its financial results and business update for the three months ended September 30, 2016. “This was another exciting quarter …
H.C.
Yesterday, at the American College of Gastroenterology’s (ACG) annual conference, Synergy Pharmaceuticals Inc (NASDAQ:SGYP) presented long-term safety data for its pipeline drug plecanatide …
By Dana Lyons A key gauge of biotechnology stocks is testing major trendline support presently – can it hold yet again? When this …
BTIG analyst Tim Chiang dives in on Synergy Pharmaceuticals Inc (NASDAQ:SGYP) after recent meetings with management have bolstered his positivity on the firm’s shares. As …
Synergy Pharmaceuticals Inc (NASDAQ:SGYP) is anticipated to release pivotal Phase 3 top-line results in IBS-C in the fourth-quarter of this year. Ahead of the …
As of the end of August 2016, Synergy Pharmaceuticals Inc (NASDAQ:SGYP) competitor Allergan has changed the language in its product label for Linzess, …
On Monday, biotech firm Synergy Pharmaceuticals Inc (NASDAQ:SGYP) reported second-quarter financial results as well as declared completion of over 95% for patient enrollment …
